142217-81-0 Usage
Description
2-Amino-1,9-dihydro-9-[(1S,3R,4S)-4-(benzyloxy)-3-(benzyloxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one is a complex organic compound characterized by its unique molecular structure. It is a derivative of 6H-purin-6-one, featuring a 2-amino group and a 1,9-dihydro ring. The compound also includes a cyclopentyl moiety with a 2-methylene group and benzyloxy and benzyloxymethyl substituents at specific stereochemical configurations.
Uses
Used in Pharmaceutical Industry:
2-Amino-1,9-dihydro-9-[(1S,3R,4S)-4-(benzyloxy)-3-(benzyloxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one is used as an intermediate in the synthesis of various pharmaceutical compounds. Its complex structure and functional groups make it a valuable building block for the development of new drugs targeting specific biological pathways.
Used in Antiviral Agents:
Specifically, 2-Amino-1,9-dihydro-9-[(1S,3R,4S)-4-(benzyloxy)-3-(benzyloxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one is used as an intermediate in the preparation of the hepatitis B antiviral agent, Entecavir (E558900). Entecavir is a nucleoside analog used for the treatment of chronic hepatitis B virus infection, and this compound plays a crucial role in its synthesis, contributing to its antiviral properties.
Chemical Properties:
The compound is described as a white powder, indicating its solid state at room temperature and typical appearance for many organic compounds. Its chemical properties, such as solubility and reactivity, would depend on the specific functional groups and stereochemistry present in its structure.
Check Digit Verification of cas no
The CAS Registry Mumber 142217-81-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,2,2,1 and 7 respectively; the second part has 2 digits, 8 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 142217-81:
(8*1)+(7*4)+(6*2)+(5*2)+(4*1)+(3*7)+(2*8)+(1*1)=100
100 % 10 = 0
So 142217-81-0 is a valid CAS Registry Number.
InChI:InChI=1/C26H27N5O3/c1-17-20(15-33-13-18-8-4-2-5-9-18)22(34-14-19-10-6-3-7-11-19)12-21(17)31-16-28-23-24(31)29-26(27)30-25(23)32/h2-11,16,20-22H,1,12-15H2,(H3,27,29,30,32)/t20-,21-,22-/m0/s1
142217-81-0Relevant articles and documents
Improved entecavir intermediate synthesis process and improved entecavir synthesis process
-
, (2020/10/14)
The invention discloses an improved entecavir intermediate synthesis process and an improved entecavir synthesis process, and relates to the technical field of drug synthesis. The invention disclosesan improved entecavir intermediate synthesis process. In the synthesis process of an amino protection reaction product, amino protecting groups are added in batches; and the ratio of the reaction rawmaterials is optimized, so that the problems of long reaction time and relatively low amino protection reaction yield due to adoption of a one-time complete feeding mode in an existing synthesis modeare solved, the synthesis time of an amino protection reaction product is shortened to 50-70 minutes, and the obtained product is high in yield and purity. According to the improved entecavir synthesis process, in the amino protection reaction product synthesis process, reaction conditions are effectively optimized, and the purity of obtained entecavir reaches 99% or above.
A New Route for the Synthesis of Entecavir
Wang, Shan-chun,Zhang, Xi-quan,Gu, Hong-mei,Zhu, Xue-yan,Guo, Ya-jun
, p. 568 - 574 (2017/12/12)
-
BMS-200475, a novel carbocyclic 2'-deoxyguanosine analog with potent and selective anti-hepatitis B virus activity in vitro
Bisacchi,Chao,Bachard,Daris,Innaimo,Jacobs,Kocy,Lapointe,Martel,Merchant,Slusarchyk,Sundeen,Young,Colonno,Zahler
, p. 127 - 132 (2007/10/03)
BMS-200475, a never carbocyclic analog of 2'-deoxyguanosine, is a potent inhibitor of hepatitis B virus in vitro (ED50 = 3 nM) with relatively low cytotoxicity (CC50 = 21-120 μM). A practical 10-step asymmetric synthesis was developed affording BMS-200475 in 18% overall chemical yield and > 99% optical purity. The enantiomer of BMS-200475 as well as the adenine, thymine, and iodouracil analogs are much less active.